Lenz Therapeutics reported Q2 2026 revenue of $5.5 million, largely from one-time licensing fees, with its main product VIZZ showing only 9% volume growth. Following this, Bank of America downgraded Lenz's stock and cut its price target from $31 to $7, citing a slow commercial launch. This caused a sharp drop in Lenz's stock price, prompting Pomerantz LLP to investigate potential securities fraud and unlawful practices by the company and its executives. Investors affected by the stock decline are encouraged to contact Pomerantz LLP for possible legal action.
Lenz Therapeutics is the subject of an investor alert following a sharp stock price drop. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: Among 91 priced US health-sector stocks, 59 rose and 31 fell. Notable movers include Illumina, Inc. (ILMN) at USD 241.64 with a 5.55% increase and a typical hold time on Pluang of 86 days, Ginkgo Bioworks Holdings Inc (DNA) at USD 7.44 up 5.38% with an 11-day hold time, and Citius Pharmaceuticals Inc (CTXR) at USD 0.58 rising 4.20% with 100% buy order activity and a 15-day hold time.
Fluence Energy's stock price target was cut sharply from $15.00 to $4.00 by RBC Capital analyst Christopher Dendrinos after the company slashed its 2026 revenue forecast from $3.00 billion to $2.40 billion. The company now expects an adjusted EBITDA ...
Regency Centers reported solid Q2 2026 results with Funds From Operations (FFO) at $1.21 per share and a 3.8% growth in same-property Net Operating Income (NOI). The company raised its full-year guidance, signaling confidence in continued growth. Reg...
Ciena reported a 37% revenue increase to $1.67 billion and a 215% rise in adjusted EPS to $2.11 in its fiscal third quarter, driven by strong demand from AI and cloud infrastructure. The company is well positioned to benefit from the AI networking ma...
Maureen Gellerman, Chief Human Resources Officer at Five Below, sold 1,610 shares of the company, generating $401,000 from the transaction. This insider sale may indicate personal financial planning or portfolio rebalancing but does not necessarily r...
ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...
